104 related articles for article (PubMed ID: 10025882)
1. Decreased HER-2 tyrosine kinase expression in rectal mucosa of FAP patients following low-dose sulindac chemoprevention.
Winde G; Lügering N; Glodny B; Schmid KW; Müller O; Senninger N; Osswald H
Cancer Lett; 1998 Dec; 134(2):201-7. PubMed ID: 10025882
[TBL] [Abstract][Full Text] [Related]
2. Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis.
Giardiello FM; Spannhake EW; DuBois RN; Hylind LM; Robinson CR; Hubbard WC; Hamilton SR; Yang VW
Dig Dis Sci; 1998 Feb; 43(2):311-6. PubMed ID: 9512123
[TBL] [Abstract][Full Text] [Related]
3. Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis.
Winde G; Schmid KW; Brandt B; Müller O; Osswald H
Dis Colon Rectum; 1997 Oct; 40(10):1156-68; discussion 1168-9. PubMed ID: 9336110
[TBL] [Abstract][Full Text] [Related]
4. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of a low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months.
Winde G; Schmid KW; Schlegel W; Fischer R; Osswald H; Bünte H
Dis Colon Rectum; 1995 Aug; 38(8):813-30. PubMed ID: 7634976
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study.
Cruz-Correa M; Hylind LM; Romans KE; Booker SV; Giardiello FM
Gastroenterology; 2002 Mar; 122(3):641-5. PubMed ID: 11874996
[TBL] [Abstract][Full Text] [Related]
6. Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac.
Keller JJ; Offerhaus GJ; Polak M; Goodman SN; Zahurak ML; Hylind LM; Hamilton SR; Giardiello FM
Gut; 1999 Dec; 45(6):822-8. PubMed ID: 10562579
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
8. Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis.
Bowen CM; Walter L; Borras E; Wu W; Ozcan Z; Chang K; Bommi PV; Taggart MW; Thirumurthi S; Lynch PM; Reyes-Uribe L; Scheet PA; Sinha KM; Vilar E
Cancer Prev Res (Phila); 2021 Sep; 14(9):851-862. PubMed ID: 34266857
[TBL] [Abstract][Full Text] [Related]
9. Tissue prostanoids as biomarkers for chemoprevention of colorectal neoplasia: correlation between prostanoid synthesis and clinical response in familial adenomatous polyposis.
Yang VW; Geiman DE; Hubbard WC; Spannhake EW; Hylind LM; Hamilton SR; Giardiello FM
Prostaglandins Other Lipid Mediat; 2000 Jan; 60(1-3):83-96. PubMed ID: 10680778
[TBL] [Abstract][Full Text] [Related]
10. Sulindac in familial adenomatous polyposis: evaluation by nuclear morphometry.
Fernández-López F; Conde-Freire R; Cadarso-Suárez C; García-Iglesias J; Puente-Domínguez JL; Potel-Lesquereux J
Eur J Surg; 2001 May; 167(5):375-81. PubMed ID: 11419555
[TBL] [Abstract][Full Text] [Related]
11. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis.
Mahmoud NN; Boolbol SK; Dannenberg AJ; Mestre JR; Bilinski RT; Martucci C; Newmark HL; Chadburn A; Bertagnolli MM
Carcinogenesis; 1998 Jan; 19(1):87-91. PubMed ID: 9472698
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms of human flavin monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis.
Hisamuddin IM; Wehbi MA; Chao A; Wyre HW; Hylind LM; Giardiello FM; Yang VW
Clin Cancer Res; 2004 Dec; 10(24):8357-62. PubMed ID: 15623613
[TBL] [Abstract][Full Text] [Related]
13. [Chemoprevention of familial cancer].
Ishikawa H
Gan To Kagaku Ryoho; 1997 Jun; 24(8):951-7. PubMed ID: 9212803
[TBL] [Abstract][Full Text] [Related]
14. The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis: clinical results of a dose-finding study on rectal sulindac administration.
Winde G; Gumbinger HG; Osswald H; Kemper F; Bünte H
Int J Colorectal Dis; 1993 Mar; 8(1):13-7. PubMed ID: 8388011
[TBL] [Abstract][Full Text] [Related]
15. Chemoprevention of familial adenomatous polyposis.
Lynch PM
Fam Cancer; 2016 Jul; 15(3):467-75. PubMed ID: 27083160
[TBL] [Abstract][Full Text] [Related]
16. Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis.
Giardiello FM; Casero RA; Hamilton SR; Hylind LM; Trimbath JD; Geiman DE; Judge KR; Hubbard W; Offerhaus GJ; Yang VW
Gastroenterology; 2004 Feb; 126(2):425-31. PubMed ID: 14762779
[TBL] [Abstract][Full Text] [Related]
17. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment.
Spagnesi MT; Tonelli F; Dolara P; Caderni G; Valanzano R; Anastasi A; Bianchini F
Gastroenterology; 1994 Feb; 106(2):362-6. PubMed ID: 8299902
[TBL] [Abstract][Full Text] [Related]
18. Sulindac increases the expression of APC mRNA in malignant colonic epithelial cells: an in vitro study.
Schnitzler M; Dwight T; Robinson BG
Gut; 1996 May; 38(5):707-13. PubMed ID: 8707116
[TBL] [Abstract][Full Text] [Related]
19. Rectal cancer after prolonged sulindac chemoprevention. A case report.
Lynch HT; Thorson AG; Smyrk T
Cancer; 1995 Feb; 75(4):936-8. PubMed ID: 7842414
[TBL] [Abstract][Full Text] [Related]
20. Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model.
Williamson T; Bai RY; Staedtke V; Huso D; Riggins GJ
Oncotarget; 2016 Oct; 7(42):68571-68584. PubMed ID: 27612418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
